DNDi passes the ball to MMV

22 May 2015

Two ACTs developed by DNDi and partners enter MMV’s portfolio

Two fixed-dose artemisinin combination therapies (ACTs) developed by Drugs for Neglected Diseases initiative (DNDi) and partners, artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ), will now be managed by MMV’s Access and Product Management team to help maximize their impact for the patients who need them most.

To commemorate the handover, MMV and DNDi convened a high-level event exploring 15 years of progress in the fight against malaria entitled: ‘Advances and challenges in the fight against malaria: a 15-year retrospective’.

Read, watch, share

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there.

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

DNDi passes the ball to MMV

DNDi passes the ball to MMV

Read, watch, share

Treating a feverish planet: The Dengue Alliance

What the G20 Coalition for Local and Regional Production, Innovation, and Equitable Access should do next

DNDi welcomes new G20 coalition focused on innovation, local and regional production, and equitable access to health tools

DNDi interventions at the 5th Meeting of the G20 Health Working Group and G20 Health Ministerial Meeting, 30-31 October 2024

The Science Explained: Evaluating an alternative treatment regimen for fungal mycetoma

Nobel prize for chemistry awarded to Demis Hassabis and John Jumper for AlphaFold, an AI model used by DNDi for neglected diseases

On World Meningitis Day, too many people are dying of cryptococcal meningitis in Africa

DNDi media fellowship for Eastern African health journalists

Help neglected patients

Learn more

Get in touch

Support us

Work with us